Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN, USA.
Department of Neuroscience, Mayo Clinic , Jacksonville, FL, USA.
Gut Microbes. 2021 Jan 1;13(1):1866974. doi: 10.1080/19490976.2020.1866974.
Parkinson's disease (PD) is a common neurodegenerative disorder characterized primarily by motor and non-motor gastrointestinal (GI) deficits. GI symptoms' including compromised intestinal barrier function often accompanies altered gut microbiota composition and motor deficits in PD. Therefore, in this study, we set to investigate the role of gut microbiota and epithelial barrier dysfunction on motor symptom generation using a rotenone-induced mouse model of PD. We found that while six weeks of 10 mg/kg of chronic rotenone administration by oral gavage resulted in loss of tyrosine hydroxylase (TH) neurons in both germ-free (GF) and conventionally raised (CR) mice, the decrease in motor strength and coordination was observed only in CR mice. Chronic rotenone treatment did not disrupt intestinal permeability in GF mice but resulted in a significant change in gut microbiota composition and an increase in intestinal permeability in CR mice. These results highlight the potential role of gut microbiota in regulating barrier dysfunction and motor deficits in PD.
帕金森病(PD)是一种常见的神经退行性疾病,主要表现为运动和非运动性胃肠道(GI)缺陷。PD 患者常伴有胃肠道症状,包括肠道屏障功能受损,肠道微生物组成改变和运动障碍。因此,在这项研究中,我们使用鱼藤酮诱导的 PD 小鼠模型,研究了肠道微生物群和上皮屏障功能障碍对运动症状产生的作用。我们发现,虽然口服灌胃 10mg/kg 的鱼藤酮持续六周导致无菌(GF)和常规饲养(CR)小鼠的酪氨酸羟化酶(TH)神经元丢失,但运动力量和协调性的下降仅在 CR 小鼠中观察到。慢性鱼藤酮处理不会破坏 GF 小鼠的肠道通透性,但会导致 CR 小鼠的肠道微生物组成发生显著变化,并增加肠道通透性。这些结果强调了肠道微生物群在调节 PD 中屏障功能障碍和运动障碍中的潜在作用。